Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome
Journal of Clinical Medicine · 03.01.2025 · 14 (1) · 239
DOI: 10.3390/jcm14010239 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Medicine, online erschienen am 03.01.2025. Verfasst von Magdalena Drozynska-Duklas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Nephrology and Hypertension, Medical University of Gdansk, 80-210 Gdansk, Poland. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Idiopathic nephrotic syndrome (INS) is the most common cause of nephrotic syndrome in children. A hallmark of the disease is the rapid remission of proteinuria following a high dose of steroids. Recurrent disease or steroid dependence are common, leading to a high steroid burden and the introduction of steroid sparing therapy. Anti-CD20 antibodies have been increasingly used with excellent results in complicated INS. Nevertheless, their use can be limited by the occurrence of infusion-related reactions (IRRs).
Methods
This report discusses further treatment options for children who are intolerant to RTX and presents the first report of a successful switch to obinutuzumab (OBI) for a child with difficult-to-treat steroid-dependent nephrotic syndrome (SDNS) and RTX intolerance who was unresponsive to a desensitization protocol.
Results
A 12-year-old boy with SDNS since the age of 2, was treated with steroids, cyclophosphamide and cyclosporine A (CsA). Because of the prolonged use of calcineurin inhibitors, a course of rituximab (RTX) was planned. Unfortunately, during first infusion, the boy presented with IRR. A desensitization protocol following the first unsuccessful infusion also failed. Facing the risks of long-term cyclosporine therapy, a decision was made to switch to another type of anti-CD20 antibody. Obinutuzumab infusion with a modified premedication scheme was uneventful.
Conclusions
Switching therapy to obinutuzumab may be considered an option in nephrotic children who are intolerant to RTX when alternative therapies have been exhausted. The addition of montelukast to premedication and employment of desensitization protocols may decrease the risk of infusion-related reactions to anti-CD20 agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Paediatrics, Nephrology and Hypertension, Medical University of Gdansk, 80-210 Gdansk, Poland.
ORCID-Profile: Magdalena Drozynska-Duklas, Anna Kranz, Ilona Chudzik
Zitieren
APA
Drozynska-Duklas, M., Kranz, A., Zagozdzon, I., Balasz-Chmielewska, I., Chudzik, I., & Zurowska, A. (2025). Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome. Journal of Clinical Medicine, 14(1), 239. https://doi.org/10.3390/jcm14010239
Vancouver
Drozynska-Duklas M, Kranz A, Zagozdzon I, Balasz-Chmielewska I, Chudzik I, Zurowska A. Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome. Journal of Clinical Medicine. 2025;14(1):239. doi:10.3390/jcm14010239
BibTeX
@article{DrozynskaDuklas2025,
author = {Drozynska-Duklas, Magdalena and Kranz, Anna and Zagozdzon, Ilona and Balasz-Chmielewska, Irena and Chudzik, Ilona and Zurowska, Aleksandra},
title = {Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {1},
pages = {239},
doi = {10.3390/jcm14010239}
}
EUVIMED